FindTrial
Sign In

Side effect profile and its correlation with genetic mutation among stomach and intestinal cancer patients who are receiving chemotherapy

Clinical profile and Correlation of DPYD gene mutation and toxicity profile among patients receiving fluoropyrimidines based chemotherapy - nil

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/05/067630
Enrollment
60
Registered
2024-05-20
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C15-C26- Malignant neoplasms of digestive organs

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

KMC MANIPAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients aged more than 18 years and older 2)Patients with GI malignancy receiving fluoropyrimidines based chemotherapy

Exclusion criteria

Exclusion criteria: 1) Patients with age less than 18years 2)Patient not consenting for DPYD testing

Design outcomes

Primary

MeasureTime frame
To correlate DPYD (Dihydropyrimidine Dehydrogenase) gene mutation and toxicity profile among patients receiving fluoropyrimidines based chemotherapy.Timepoint: DPYD mutation testing - at baseline, before starting chemotherapy—

Secondary

MeasureTime frame
Prevalence of DPYD gene mutation & its allelic variants among patients receiving fluoropyrimidines based chemotherapy Association of DPYD genotype with toxicity profile among patients receiving fluoropyrimidines based chemotherapyTimepoint: toxicity profile will be documented at 4 weeks , 8 weeks & 24 weeks—

Countries

India

Contacts

Public ContactNiranjan G M

Kasturba Medical college, Manipal

udupa.k@gmail.com9845317153

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026